Publicaciones (401) Publicaciones de LUIS GONZAGA PAZ-ARES RODRÍGUEZ

2024

  1. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study

    Journal of Thoracic Oncology, Vol. 19, Núm. 2, pp. 285-296

  2. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 192-204

  3. Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 180-191

  4. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial

    Lung Cancer, Vol. 189

  5. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

    The Lancet Regional Health - Europe, Vol. 38

  6. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

  7. Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

    Clinical Cancer Research, Vol. 30, Núm. 4, pp. 824-835

  8. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach

    Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326

  9. Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 985-990

  10. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)

    Lung Cancer, Vol. 187

  11. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 2

  12. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases

    Lung Cancer, Vol. 188

  13. Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study

    Future oncology (London, England), Vol. 20, Núm. 6, pp. 297-306

  14. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

  15. Sotorasib in KRASG12C mutated lung cancer – Authors' reply

    The Lancet

  16. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

2023

  1. A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma

    Translational Lung Cancer Research, Vol. 12, Núm. 7, pp. 1549-1562

  2. Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer

    Cancers, Vol. 15, Núm. 5

  3. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

    New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2039-2051

  4. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

    JTO Clinical and Research Reports, Vol. 4, Núm. 1